- Doximity Inc DOCS reported fourth-quarter revenue growth of 40.4% year-over-year to $93.7 million, beating the consensus of $90.11 million.
- Adjusted net income was $44.9 million versus $24 million in 4Q21, representing a 48% margin.
- Adjusted EPS was $0.21, beating the consensus of $0.15.
- Adjusted gross margin expanded by 200 bps to 90%. The adjusted operating income improved 47% Y/Y to $38.24 million, and the margin expanded by 183 bps to 40.8%.
- Adjusted EBITDA improved 47.2% Y/Y to $39.35 million, and margin expanded by 193 bps to 42%.
- Doximity generated cash from operating activities for FY22 of $126.57 million, compared to $82.96 million a year ago. Free cash flow of $120.88 million.
- Buyback: Doximity authorized a new stock repurchase program to acquire up to $70 million of its Class A common stock, commencing in1Q23.
- "We're proud to now serve over 2 million US healthcare professionals, including over 80% of US physicians and over 50% of Physician Assistants and Nurse Practitioners. This quarter, we added scheduling to our product suite with the acquisition of Amion, and saw record use of our fax, e-signature, and telehealth tools.," commented Jeff Tangney, co-founder & CEO at Doximity.
- 1Q23 Outlook: Doximity expects revenue of $88.6 million - $89.6 million vs. a consensus of $96.78 million and Adjusted EBITDA of $28.6 million and $29.6 million.
- FY23 Outlook: The company expects revenue of $454 million - $458 million vs. a consensus of $452.12 million and Adjusted EBITDA of $192 million and $196 million.
- Price Action: DOCS shares are trading lower by 18.10% at $27.75 during the post-market session on Tuesday.
- Photo via Company
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
